NCT03508349

Brief Summary

The main aim of this study is to test the primary hypothesis that the addition of intermittent screening and treatment of malaria in pregnant women (ISTp) who receive routine antenatal care (ANC) in health facilities in high malaria transmission areas in Rwanda will reduce malaria prevalence among pregnant women when compared to routine antenatal cares services alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,786

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2016

Typical duration for not_applicable

Geographic Reach
1 country

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 5, 2016

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

January 23, 2018

Completed
3 months until next milestone

First Posted

Study publicly available on registry

April 25, 2018

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 18, 2019

Completed
Last Updated

December 6, 2019

Status Verified

December 1, 2019

Enrollment Period

2.2 years

First QC Date

January 23, 2018

Last Update Submit

December 4, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of placental malaria at delivery (tested by PCR)

    comparison of prevalence of malaria between women in intervention and control sites

    at the time of delivery

Secondary Outcomes (4)

  • Prevalence of maternal anemia at delivery

    at the time of delivery

  • Prevalence of low birth weight babies (<37 weeks gestation)

    at the time of delivery

  • Prevalence of preterm births

    at the time of delivery

  • Episodes of clinical malaria during the course of the pregnancy

    assessed at the time of delivery

Other Outcomes (1)

  • Adverse outcome of pregnancy - abortions, still births and neonatal deaths

    assessed at the time of delivery

Study Arms (2)

IST using RDT

EXPERIMENTAL

Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.

Diagnostic Test: IST

Routine Antenatal Care

NO INTERVENTION

Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.

Interventions

ISTDIAGNOSTIC_TEST

Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.

IST using RDT

Eligibility Criteria

Age18 Years - 49 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailspregnant at the time of enrollment in the study
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Pregnant women age 18 or older who have their first ANC visit during the study recruitment period
  • Willing to participate

You may not qualify if:

  • Pregnant women below the age of 18
  • Not willing to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Busoro-Gishamvu Health Center

Huye, South, Rwanda

Location

Huye Police Health Center

Huye, South, Rwanda

Location

Maraba Health Cente

Huye, South, Rwanda

Location

Mukura Health Center

Huye, South, Rwanda

Location

Rango Health Center

Huye, South, Rwanda

Location

Rubona Health Center

Huye, South, Rwanda

Location

Rwaniro

Huye, South, Rwanda

Location

Sovu Health Center

Huye, South, Rwanda

Location

Kamonyi Health Center

Kamonyi, South, Rwanda

Location

Kayenzi Health Center

Kamonyi, South, Rwanda

Location

Mugina Health Center

Kamonyi, South, Rwanda

Location

Musambira Health Center

Kamonyi, South, Rwanda

Location

Nyagihamba Health Center

Kamonyi, South, Rwanda

Location

Nyamiyaga Health Center

Kamonyi, South, Rwanda

Location

Related Publications (2)

  • Alruwaili M, Uwimana A, Sethi R, Murindahabi M, Piercefield E, Umulisa N, Abram A, Eckert E, Munguti K, Mbituyumuremyi A, Gutman JR, Sullivan DJ. Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda. Am J Trop Med Hyg. 2023 Oct 2;109(5):1057-1062. doi: 10.4269/ajtmh.23-0225. Print 2023 Nov 1.

  • Uwimana A, Sethi R, Murindahabi M, Ntirandeka C, Piercefield E, Umulisa N, Abram A, Eckert E, Munguti K, Sullivan D, Uyizeye D, Mbituyumuremyi A, Gutman JR. Effectiveness of Intermittent Screening and Treatment of Malaria in Pregnancy on Maternal and Birth Outcomes in Selected Districts in Rwanda: A Cluster Randomized Controlled Trial. Clin Infect Dis. 2023 Jul 5;77(1):127-134. doi: 10.1093/cid/ciad128.

Study Officials

  • Reena Sethi, DrPH

    Jhpiego

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Health facilities in high malaria transmission zones were pair matched and then randomized to be an intervention or a control facility.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 23, 2018

First Posted

April 25, 2018

Study Start

September 5, 2016

Primary Completion

October 31, 2018

Study Completion

March 18, 2019

Last Updated

December 6, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations